NLRP3 and chronic kidney disease: Thus, DIO’s therapeutic efficacy in DN may arise from its concurrent targeting of NLRP3-driven renal fibrosis and gut barrier preservation, highlighting the interconnectedness of mucosal immunity and chronic kidney disease pathogenesis.